Market closed
ChromaDex/$CDXC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ChromaDex
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
Ticker
$CDXC
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
106
Website
ChromaDex Metrics
BasicAdvanced
$452M
299.86
$0.02
1.86
-
Price and volume
Market cap
$452M
Beta
1.86
52-week high
$7.60
52-week low
$1.46
Average daily volume
441K
Financial strength
Current ratio
2.946
Quick ratio
2.274
Long term debt to equity
5.455
Total debt to equity
8.423
Management effectiveness
Return on assets (TTM)
0.51%
Return on equity (TTM)
4.82%
Valuation
Price to earnings (TTM)
299.858
Price to revenue (TTM)
4.858
Price to book
13.08
Price to tangible book (TTM)
13.23
Price to free cash flow (TTM)
109.678
Growth
Revenue change (TTM)
9.95%
Earnings per share change (TTM)
-121.43%
3-year revenue growth (CAGR)
12.06%
3-year earnings per share growth (CAGR)
-64.21%
What the Analysts think about ChromaDex
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ChromaDex stock.
ChromaDex Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ChromaDex Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ChromaDex News
AllArticlesVideos
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Business Wire·3 weeks ago
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
Business Wire·2 months ago
ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ChromaDex stock?
ChromaDex (CDXC) has a market cap of $452M as of January 31, 2025.
What is the P/E ratio for ChromaDex stock?
The price to earnings (P/E) ratio for ChromaDex (CDXC) stock is 299.86 as of January 31, 2025.
Does ChromaDex stock pay dividends?
No, ChromaDex (CDXC) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next ChromaDex dividend payment date?
ChromaDex (CDXC) stock does not pay dividends to its shareholders.
What is the beta indicator for ChromaDex?
ChromaDex (CDXC) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.